UNSPSC 51401904: Fasiplon

This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C13H15N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XCA050IPGB, chemically known as 6-ethyl-7-methoxy-5-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo(1,2-a)pyrimidine. but generally known as fasiplon, which bears US NIH Compound Identifier 208954. European Medicines Agency schedules Fasiplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07514MIG.

UNSPSC 51401904 Fasiplon, a Commodity code, represents pharmaceutical products and systems that state and local health agencies procure to support public health initiatives and community health programs. Recent state and local opportunities under this code show demand for naloxone kits and drug deactivation systems for emergency response and harm reduction, generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesale channels to government facilities, and direct-to-manufacturer prescription fulfillment capabilities to improve cost management within state pharmacy benefit programs. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that coordinate procurement across multiple jurisdictions. The scope of work spans both acute-need supplies (emergency naloxone and drug disposal systems) and ongoing pharmaceutical inventory management through tiered supply chains involving manufacturers, wholesalers, and end-use facilities.

Recent activity concentrates in Florida and the Upper Midwest. Seminole County, Florida released an Invitation for Bid (IFB 60459723LAS) in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued a Request for Proposal (S1070000015802) in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed to participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness on July 1, 2026. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for implementing a Therapeutic Pharmacy Initiative, signaling preliminary state interest in restructuring pharmacy benefit procurement outside traditional pharmacy benefit manager and group purchasing organization channels.